Mechanism and progress of exosomes in the treatment of nonunion

doi:10.3969/j.issn.2095-4344.2801

Abstract

Abstract:

BACKGROUND: Bone nonunion is a common complication after fracture, which brings great distress to patients. With the continuous development of exosomal technology, exosomes gradually show their advantages in the treatment of nonunion, which has become a new research direction in medical work.

OBJECTIVE: To summarize the researches in and outside China and explore the role of exosomes in the treatment of nonunion.

METHODS: The authors retrieved related Chinese articles published from 2003 to 2019 in Wanfang database, CNKI and VIP database with the key words of “exosomes, nonunion, bone remodeling, bone regeneration, vascular injury, osteoblasts, osteoclasts” and related English articles published from 2003 to 2019 in PubMed with the key words of “exosomes, nonunion, bone remodeling”. Totally 50 articles were selected based on inclusion and exclusion criteria.

RESULTS AND CONCLUSION: (1) In recent years, more and more attention has been paid to the study of exosomes on bone nonunion. MiRNAs and proteins in exosomes can affect bone nonunion by affecting the differentiation of osteocytes. (2) Studies have found that exosomes can treat bone nonunion by regulating bone remodeling, promoting vascular repair, and improving systemic diseases. (3) However, the current research on exosomes is still in the experimental stage. The specific method of how to better apply it to clinical treatment needs further exploration.

Key words: exosomes, bone nonunion, miRNA, bone remodeling, vascular injury

CLC Number:

Lai Yu, Han Jie. Mechanism and progress of exosomes in the treatment of nonunion[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(27): 4349-4355.

Figures/Tables 3

References

[1] CALORI GM. Non-unions. Clinical Cases in Mineral & Bone Metabolism the Official Journal of the Italian Society of Osteoporosis Mineral Metabolism & Skeletal Diseases, 2017;14(2):186-188.

[2] 骆永锋,龚劲纯,吴俊,等.带锁髓内钉治疗四肢创伤骨折后骨不连的临床研究[J]. 齐齐哈尔医学院学报,2017,38(2):193-195.

[3] WU KJ, LI SH, YEH KT, et al. The risk factors of nonunion after intramedullary nailing fixation of femur shaft fracture in middle age patients. Medicine(Baltimore). 2019;98:e16559.

[4] YANEZ-MO M, SIJANDER PR, ANDREU Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4(1):27066.

[5] 李晓晔,周潇逸,张子程,等.外泌体中miRNA对骨重建过程影响研究进展[J].中国矫形外科杂志,2019,27(18):1683-1686.

[6] 赵濛,刘志红,李金泉.外泌体组成特征及其作为细胞通讯和分子标记的生物学作用[J].中国生物化学与分子生物学报, 2016, 32(6):612-619.

[7] LU J,WANG QY,SHENG JG, et al. Exosomes in the repair of bone defects: next-generation therapeutic tools for the treatment of nonunion. Biomed Res Int. 2019;2019: 1983131.

[8] 寿崟,马宇航,虎力,等.外泌体在糖尿病及其并发症的发生、发展和诊治中的作用[J].生理学报,2019,71(6):917-934.

[9] LU Z, ZUO B, JING R, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67: 739-748.

[10] EL-SAGHIR J, NASSAR F, TAWIL N, et al. ATL-derived exosomes modulate mesenchymal stem cells: potential role in leukemia progression. Retrovirology. 2016; 13: 73.

[11] BRAICU C, TOMULEASA C, MONROIG P, et al. Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ. 2015;22: 34-45.

[12] POURAKBARI R, KHODADADI M, AGHEBATI-MALEKI A, et al. The potential of exosomes in the therapy of the cartilage and bone complications; emphasis on osteoarthritis. Life Sci. 2019;236: 116861.

[13] YAN Z, GUO Y, WANG Y, et al. MicroRNA profiles of BMSCs induced into osteoblasts with osteoinductive medium. Exp Ther Med. 2018;15: 2589-2596.

[14] HAMMOND SM. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett. 2005;579: 5822-5829.

[15] HUTVAGNER G. Small RNA asymmetry in RNAi: Function in RISC assembly and gene regulation. Febs Lett. 2005;579(26): 5850-5857.

[16] WEILNER S, SCHRAML E, REDL H, et al. Secretion of microvesicular miRNAs in cellular and organismal aging. Exp Gerontol. 2013;48(7):626-633.

[17] ZHANG Y, XIE RL, CROCE CM, et al. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc Natl Acad Sci U S A. 2011;108(24):9863-9868.

[18] LI Z, HASSAN MQ, VOLINIA S, et al. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci U S A. 2008;105(37): 13906-13911.

[19] LIU Y, MA Y, ZHANG J, et al. Exosomes: a novel therapeutic agent for cartilage and bone tissue regeneration. Dose Response. 2019;17: 1559325819892702.

[20] XU JF, YANG GH, PAN XH, et al. Altered microrna expression profile in exosomes during osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. PLoS ONE. 2014;9(12):e114627.

[21] GE M, KE R, CAI T, et al. Identification and proteomic analysis of osteoblast-derived exosomes. Biochem Biophys Res Commun. 2015;467(1):27-32.

[22] SHRESTHA N, BAHNAN W, WILEY DJ, et al. Eukaryotic Initiation Factor 2 (eIF2) signaling regulates proinflammatory cytokine expression and bacterial invasion. J Biol Chem. 2012; 287(34):28738-28744.

[23] AKTAS BH, BORDELOIS P, PEKER S, et al. Depletion of eIF2·GTP·Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo. Oncotarget. 2015;6:6902-6914.

[24] JOHNSON ME, DELIARD S, ZHU F, et al. A ChIP-seq-defined genome-wide map of MEF2C binding reveals inflammatory pathways associated with its role in bone density determination. Calcif Tissue Int. 2014;94(4):396-402.

[25] TANAKA KI, KAJI H, YAMAGUCHI T, et al. Involvement of the Osteoinductive Factors, Tmem119 and BMP-2, and the ER Stress Response PERK–eIF2α–ATF4 Pathway in the Commitment of Myoblastic into Osteoblastic Cells. Calcif Tissue Int. 2014;94(4):454-464.

[26] YANG X, MATSUDA K, BIALEK P, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell. 2015;117(3): 387-398.

[27] NOJIMA H, TOKUNAGA C, EGUCHI S, et al. The Mammalian Target of Rapamycin (mTOR) Partner, Raptor, Binds the mTOR Substrates p70 S6 Kinase and 4E-BP1 through Their TOR Signaling (TOS) Motif. J Biol Chem. 2003;278(18): 15461-15464.

[28] JACINTO E, LOEWITH R, SCHMIDT A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6(11):1122-1128.

[29] LI X, CHANG B, WANG B, et al. Rapamycin promotes osteogenesis under inflammatory conditions. Mol Med Rep. 2017; 16: 8923-8929.

[30] SUN H, KIM JK, MORTENSEN RM, et al. Osteoblast-targeted Suppression of PPARγ Increases Osteogenesis through Activation of mTOR Signaling. Stem Cells. 2013;31: 2183-2192.

[31] LONG H, ZHU Y, LIN Z, et al. miR-381 modulates human bone mesenchymal stromal cells (BMSCs) osteogenesis via suppressing Wnt signaling pathway during atrophic nonunion development. Cell Death Dis. 2019;10: 470.

[32] XIE Y, CHEN Y, ZHANG L, et al. The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling. J Cell Mol Med. 2017;21: 1033-1041.

[33] MOHAMMED MK,SHAO C,WANG J,et al. Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis.2016;3(1):11-40.

[34] CUI Y, LUAN J, LI H, et al. Exosomes derived from mineralizing osteoblasts promote ST2 cell osteogenic differentiation by alteration of microRNA expression. FEBS Lett. 2016; 590(1):185-192.

[35] HASSAN MQ, MAEDA Y, TAIPALEENMAKI H, et al. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem. 2012;287(50):42084-42092.

[36] NEGISHI-KOGA T, SHINOHARA M, KOMATSU N, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nature Med. 2011;17(11):1473-1480.

[37] SUN W, ZHAO C, LI Y, et al. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov. 2016; 2:16015.

[38] LI D, LIU J, GUO B, et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nature Commun. 2016;7:10872.

[39] DI LEVA G, CHEUNG DG, BUZZETTI M. miRNAs in bone metastasis. Exp Rev Endocrinol Metabol. 2017: 17446651.2017.1383893.

[40] HUYNH N, VONMOSS L, SMITH D, et al. Characterization of regulatory extracellular vesicles from osteoclasts. J Dent Res. 2016:0022034516633189.

[41] MARTINS M, RIBEIRO D, MARTINS A, et al. Extracellular vesicles derived from osteogenically induced human bone marrow mesenchymal stem cells can modulate lineage commitment. Stem Cell Rep. 2016; 6(3):284-291.

[42] QIN Y, WANG L, GAO Z, et al. Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo. Sci Rep. 2016; 6:21961.

[43] 陈燕,姜胜军,彭友俭.骨髓间充质干细胞来源的外泌体对成骨细胞增殖和分化的影响[J].口腔医学研究,2019,35(4):401-404.

[44] 刘一飞,王宇辰,朱昱,等.尿源性干细胞的外泌体修复骨不连的作用研究[J].上海医学,2019,42(7):411-417.

[45] LIANG X, ZHANG L, WANG S, et al. Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J Cell Sci. 2016; 129(11):2182-2189.

[46] KUCHARZEWSKA P, CHRISTIANSON HC, WELCH JE, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013;110(18): 7312-7317.

[47] LI XC, CHEN CY, WEI LM, et al. Exosomes derived from endothelial progenitor cells attenuate vascular repair and accelerate reendothelialization by enhancing endothelial function. Cytotherapy. 2016;18(2):253-262.

[48] ABDELALI A, PIERRE-HENRI D, TAREK B, et al. Microparticles from patients with metabolic syndrome induce vascular hypo-reactivity via fas/fas-ligand pathway in mice. PLoS ONE. 2011; 6(11):e27809.

[49] SU T, XIAO Y, XIAO Y, et al. Bone marrow mesenchymal stem cells-derived exosomal mir-29b-3p regulates aging-associated insulin resistance. ACS Nano. 2019;13: 2450-2462.

[50] FURUTA T, MIYAKI S, ISHITOBI H, et al. Mesenchymal stem cell-derived exosomes promote fracture healing in a mouse model. Stem Cells Transl Med. 2016;5(12):1620-1630.